Gastritis (Gastrointestinal) - Drugs in Development, 2021

Gastritis (Gastrointestinal) - Drugs in Development, 2021

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Drugs In Development, 2021, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 2, 5 and 1 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Gastritis - Overview
Gastritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Gastritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastritis - Companies Involved in Therapeutics Development
Addpharma Inc
Allakos Inc
CalyGene Biotechnology Inc
Daewon Pharmaceutical Co Ltd
GNT Pharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kyowa Kirin Co Ltd
Marinomed Biotech AG
Otsuka Holdings Co Ltd
Recce Pharmaceuticals Ltd
RedHill Biopharma Ltd
Trio Medicines Ltd
Gastritis - Drug Profiles
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DW-1903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIP-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-2150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lirentelimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAM-20101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebamipide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebamipide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastritis - Dormant Projects
Gastritis - Product Development Milestones
Featured News & Press Releases
Jun 07, 2021: Allakos completes patient enrollment in phase 3 eosinophilic gastritis and/or eosinophilic duodenitis and phase 2/3 eosinophilic esophagitis clinical trials of lirentelimab (AK002)
Dec 08, 2020: Rebamipid, which has risen in price, imminent commercialization of domestically developed western-release tablets
Oct 26, 2020: Results from prospective prevalence study indicate that eosinophilic gastritis and eosinophilic duodenitis may be significantly underdiagnosed
Oct 26, 2020: Allakos announces results from a phase 1 study of subcutaneously administered lirentelimab (AK002)
Oct 21, 2020: Anti-Siglec-8 Antibody trial shows promise for treating Eosinophilic gastritis and duodenitis
Oct 21, 2020: Allakos announces publication of results from the phase 2 study of lirentelimab (AK002) in patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
Jun 03, 2020: Allakos initiates patient recruitment for AK002 registrational studies
May 04, 2020: Allakos announces positive interim results from an open-label extension study of Antolimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis
Apr 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the 2020 DDW Annual Meeting
Mar 24, 2020: Allakos announces positive phase 1 results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease
Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gastritis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Gastritis - Pipeline by Addpharma Inc, 2021
Gastritis - Pipeline by Allakos Inc, 2021
Gastritis - Pipeline by CalyGene Biotechnology Inc, 2021
Gastritis - Pipeline by Daewon Pharmaceutical Co Ltd, 2021
Gastritis - Pipeline by GNT Pharma Co Ltd, 2021
Gastritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Gastritis - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
Gastritis - Pipeline by Kyowa Kirin Co Ltd, 2021
Gastritis - Pipeline by Marinomed Biotech AG, 2021
Gastritis - Pipeline by Otsuka Holdings Co Ltd, 2021
Gastritis - Pipeline by Recce Pharmaceuticals Ltd, 2021
Gastritis - Pipeline by RedHill Biopharma Ltd, 2021
Gastritis - Pipeline by Trio Medicines Ltd, 2021
Gastritis - Dormant Projects, 2021
List of Figures
Number of Products under Development for Gastritis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook